BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

Adherium wins US clearance for GSK inhaler users to connect to new platform

27 July 2022 | News

Adherium receives U.S. FDA 510(k) clearance for Ellipta inhaler users to connect to Hailie platform with physiological parameters

Australia's Adherium, a leader in respiratory eHealth, remote monitoring and data management solutions, has received US Food and Drug Administration (FDA) 510(k) clearance to market application connecting GlaxoSmithKline's (GSK) Ellipta inhaler users with Adherium's new, next generation Hailie sensor with physiological parameters for monitoring Asthma and Chronic obstructive pulmonary disease (COPD) medication use.

Following market clearance of the Hailie sensor with physiological parameters for AstraZeneca's Symbicort pMDI inhaler, Adherium's latest Hailie sensor is designed for use with the Breo, Anoro, Incruse, Trelegy and Arnuity Ellipta dry powder inhalers (DPIs), and captures physiological parameters, including inhalation duration, volume, and peak inhalation flow. This new series of devices provide a superior perspective into inhaler usage and technique giving patients and doctors immediate, real-time feedback thereby allowing patients to improve their quality of life and enabling physicians to enhance patient care by capturing clinical data supporting patient management and treatment.

Adherium continues its global expansion strategy to extend its digital technological innovations to enable reimbursement on 18 of the top 20 US branded inhaler medications in CY23.